News

Researchers conducted a comprehensive review of ACD, detailing the condition’s epidemiology, pathophysiology, clinical manifestations, diagnostic approaches, and therapeutic options.

The guide prepares students to critically engage with AI tools and understand their real-world implications.

Long-pulsed KTP laser showed promise as a safe, effective alternative to PDL for treating port-wine birthmarks over 3 years.

Current JAK inhibitors are approved only for those 12 and older, leaving younger patients without access.

Tofacitinib showed promise for easing itch and skin symptoms in prurigo nodularis, though effects may lessen over time.

Explore key takeaways from AAD 2025, rosacea insights, psoriasis updates, and expert interviews in the latest issue of Dermatology Times.

The method was safe and effective with high patient satisfaction rates 4 weeks post-injection.

Explore the top headlines of the week including insights on pandemic risks, weight loss medications, and more.

Test your knowledge of key words and terms associated with dermatology news from the previous week.

In case you missed it, this week we had news about pregnancy-related skin changes, art in clinical spaces, Allergan's upcoming skin quality index, and more.

This week, we feature top articles from our sister publications on the future of health care, FDA approvals, and more.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Allergan’s latest initiative hopes to empower both patients and clinicians while advancing industry standards, according to Sherket Peterson, PhD.

A cross-sectional survey revealed that many patients with HS are dissatisfied with treatment options, with gaps in knowledge about FDA-approved therapies.

The study found dupilumab-treated patients had the highest probability of remaining infection-free over 52 weeks.

Sherket Peterson, PhD, spoke to Dermatology Times about Allergan’s recent research and plan to launch a universal skin quality index.

Studies show that exposure to meaningful artwork can lower blood pressure and enhance mental clarity in patients.

Tremfya is the first IL-23 inhibitor to significantly improve both symptoms and structural damage in active psoriatic arthritis.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Unlike biologics, nonbiologic systemic therapies showed a neutral or slightly increased cardiovascular risk, raising concerns about their long-term safety.

Jiyeon Oh’s research confirms that a personalized approach is needed to treat all complexities associated with AD.

Researchers reported the case of a 28-year-old woman with epidermodysplasia verruciformis who developed SCC on a sun-protected scalp.

The study stated early recognition and aggressive treatment of childhood-onset MMP are essential to prevent permanent scarring.

Researcher Jiyeon Oh shares results of a recent study that confirm the prevalence of AD is stable, but disease burden is rising.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Hand eczema affects 22.4% of adults in East Greenland, with prevalence, severity, and risk factors mirroring trends other populations.

Get a glimpse of the cutting-edge atopic dermatitis research, breakthroughs, and insights to be presented at the 7th RAD Annual Meeting, June 6-7, 2025.

Positive changes in DLQI scores were observed after 4 weeks of therapy as well as the 6-month follow-up.

Researchers call for standardized methods to assess and report ADWEs in deprescribing trials to ensure reliable data and clinical confidence.

Mount Sinai is celebrating one year since the establishment of the Mount Sinai-Clinique Healthy Skin Dermatology Center.